At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ELDN Eledon Pharmaceuticals, Inc.
Pre-Mkt 01-28 07:23:50 EST
2.20
-0.01
-0.45%
High2.22Low2.16Vol348.96K
Open2.20D1 Closing2.21Amplitude2.67%
Mkt Cap165.08MTradable Cap120.64MTotal Shares75.03M
T/O766.19KT/O Rate0.64%Tradable Shares54.83M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Eledon Pharmaceuticals Reports Positive 24-Month Phase 1b Data for Tegoprubart in Kidney Transplant Patients
Reuters  ·  01-26 14:51
Eledon Pharmaceuticals Reports Positive 24-Month Phase 1b Data for Tegoprubart in Kidney Transplant Patients
Analysts Conflicted on These Healthcare Names: Ufp Technologies (UFPT), Eledon Pharmaceuticals (ELDN) and CareDx (CDNA)
TIPRANKS  ·  01-23
Analysts Conflicted on These Healthcare Names: Ufp Technologies (UFPT), Eledon Pharmaceuticals (ELDN) and CareDx (CDNA)
Eledon Pharmaceuticals Inc - Funds Expected to Support Operations Into 2Q 2027
THOMSON REUTERS  ·  01-09
Eledon Pharmaceuticals Inc - Funds Expected to Support Operations Into 2Q 2027
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
GlobeNewswire  ·  01-09
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
Eledon Pharmaceuticals Swaps Shares for Pre-Funded Warrants in Private Exchange
Reuters  ·  01-03
Eledon Pharmaceuticals Swaps Shares for Pre-Funded Warrants in Private Exchange
Eledon Pharmaceuticals CEO to Join Fireside Chat at Piper Sandler Healthcare Conference
Reuters  ·  2025-12-01
Eledon Pharmaceuticals CEO to Join Fireside Chat at Piper Sandler Healthcare Conference
Eledon Pharmaceuticals Shares Rise About 10% to $1.69 in Active Trading Volume After the Bell Following Preliminary Update on Drug Test in Diabetes Patients
THOMSON REUTERS  ·  2025-11-19
Eledon Pharmaceuticals Shares Rise About 10% to $1.69 in Active Trading Volume After the Bell Following Preliminary Update on Drug Test in Diabetes Patients
BRIEF-Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant
Reuters  ·  2025-11-19
BRIEF-Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant
Eledon Pharmaceuticals Reports Promising Early Results for Tegoprubart in Islet Transplant Trial for Type 1 Diabetes
Reuters  ·  2025-11-19
Eledon Pharmaceuticals Reports Promising Early Results for Tegoprubart in Islet Transplant Trial for Type 1 Diabetes
Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at Uchicago Medicine
THOMSON REUTERS  ·  2025-11-19
Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at Uchicago Medicine
Eledon Pharmaceuticals Inc - Tegoprubart Well Tolerated, No Serious Infections or Rejection Events
THOMSON REUTERS  ·  2025-11-19
Eledon Pharmaceuticals Inc - Tegoprubart Well Tolerated, No Serious Infections or Rejection Events
Eledon Pharmaceuticals Is Maintained at Buy by Guggenheim
Dow Jones  ·  2025-11-18
Eledon Pharmaceuticals Is Maintained at Buy by Guggenheim
Eledon Pharmaceuticals price target lowered to $8 from $9 at Guggenheim
TIPRANKS  ·  2025-11-18
Eledon Pharmaceuticals price target lowered to $8 from $9 at Guggenheim
Eledon Pharma Q3 EPS $(0.21) Beats $(0.24) Estimate
Benzinga  ·  2025-11-15
Eledon Pharma Q3 EPS $(0.21) Beats $(0.24) Estimate
Eledon Pharmaceuticals posts Q3 net loss of $17.5 million
Reuters  ·  2025-11-15
Eledon Pharmaceuticals posts Q3 net loss of $17.5 million
Eledon Pharmaceuticals Q3 Operating Expenses USD 19.07 Million
THOMSON REUTERS  ·  2025-11-15
Eledon Pharmaceuticals Q3 Operating Expenses USD 19.07 Million
Eledon Pharmaceuticals Q3 Income From Operations USD -19.07 Million
THOMSON REUTERS  ·  2025-11-15
Eledon Pharmaceuticals Q3 Income From Operations USD -19.07 Million
Press Release: Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Dow Jones  ·  2025-11-15
Press Release: Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Top News Today: Stocks Mixed as AI Selloff Slows
Dow Jones  ·  2025-11-15
Top News Today: Stocks Mixed as AI Selloff Slows
Eledon Pharmaceuticals Shares Sink After Pricing $50M Public Offering
Dow Jones  ·  2025-11-12
Eledon Pharmaceuticals Shares Sink After Pricing $50M Public Offering

Introduction

Company Name.
Eledon Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Issue price:
--